A Selective and Sensitive Method Development and Validation for Impurity Quantification in Cysteamine Bitartrate Bulk and Formulation by RP‐HPLC
Biomedical Chromatography · 2025
DOI: 10.1002/bmc.70007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, 2025. Verfasst von Prasanth Katakam und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Vignan's Foundation for Science Technology & Research, Guntur, Andhra Pradesh, India. Hauptthemen laut MEDLINE: Drug Contamination, Cysteamine, Chromatography, Reverse-Phase. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
RP‐HPLC was used to develop and validate a simple, selective, and sensitive impurity quantification method for cysteamine bitartrate formulation. Chromatographic separation was achieved using Shim‐pack Sceptre HD‐C 18 ‐5 μm 4.6 × 250 mm column. The mobile phase‐A was 43 mM 1‐hexane sulfonic acid sodium salt monohydrate buffer adjusted to pH 2.2 with 0.1% orthophosphoric acid. Mobile phase‐B was acetonitrile. The column oven temperature was 40°C, and gradient elution was done at 0.8 mL per minute, and the gradient program was T/A: 0/100, 12/100, 12.1/90, 30/80, 35/70, 45/70, 45.1/100, and 60/100. To measure component quantities, a 200 nm wavelength and 10 μL injection volumes were utilized. The drug product and drug substance were subjected to the stress conditions such as acid, base, oxidation, heat, and photolysis as per the recommendations of the International Conference on Harmonization (Q2) methodology. Stress research shows that the approach is stable and peak homogeneous. High accuracy (97%–103% recoveries), precision (≤ 1.0%), specificity (R2 > 0.999), and linearity (R2 > 0.999) were achieved with the approach. The detection limit (LOD) was 0.3 μg mL −1 , whereas the quantification limit (LOQ) was 1.0 μg mL −1 . The analytical method was validated according to ICH and USP < 1225 > guidelines. For quality control, the method was exact, particular, linear, accurate, and resilient.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Vignan's Foundation for Science Technology & Research, Guntur, Andhra Pradesh, India.
- Analytical Research and Development, Rising Pharma Specialities Private Limited, Hyderabad, Telangana, India.
- Analytical Research and Development, Ascent Pharmaceuticals Inc, Central Islip, New York, USA.
ORCID-Profile: Prasanth Katakam
Zitieren
APA
Katakam, P., Pathak, U. N., Chollety, V. K., & Tripuramallu, B. K. (2025). A Selective and Sensitive Method Development and Validation for Impurity Quantification in Cysteamine Bitartrate Bulk and Formulation by RP‐HPLC. Biomedical Chromatography. https://doi.org/10.1002/bmc.70007
Vancouver
Katakam P, Pathak UN, Chollety VK, Tripuramallu BK. A Selective and Sensitive Method Development and Validation for Impurity Quantification in Cysteamine Bitartrate Bulk and Formulation by RP‐HPLC. Biomedical Chromatography. 2025. doi:10.1002/bmc.70007
BibTeX
@article{Katakam2025,
author = {Katakam, Prasanth and Pathak, Umesh N and Chollety, Vijay Kumar and Tripuramallu, Bharat Kumar},
title = {A Selective and Sensitive Method Development and Validation for Impurity Quantification in Cysteamine Bitartrate Bulk and Formulation by RP‐HPLC},
journal = {Biomedical Chromatography},
year = {2025},
doi = {10.1002/bmc.70007}
}
EUVIMED